Single Domain Antibody Platform Market
Single Domain Antibody Platform Market Study by Multi-specific, Bispecific, Multivalent, and Mono-specific for Diagnostic Development, Therapeutic Development, and R&D Activities from 2024 to 2034
Analysis of Single Domain Antibody Platform Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Single Domain Antibody Platform Market Outlook (2024 to 2034)
The global single domain antibody platform market size is projected to increase from a size of US$ 32.9 million in 2024 to US$ 86 million by the end of 2034, expanding at a CAGR of 10.1% over the next decade.
Adoption of single domain antibody platforms is increasing due to the rising need for novel treatments to improve results due to a rise in the prevalence of immune disorders, viral infections, and cancer. This factor is helping raise awareness about the benefits of single-domain antibody platforms.
With businesses struggling to meet changing healthcare needs and legal requirements, the single domain antibody platform market size is projected to expand at a significant pace during the forecast period, creating lucrative opportunities for manufacturers.
Demand for single domain antibody platforms is growing at a significant pace because of their role in therapeutic development, notably in treating immune disorders, viral infections, and cancer. These platforms present several advantages over conventional antibodies. These include their smaller size, reduced production costs, and superior ability to fight diseases.
Effectiveness of immune and antiviral therapies can be improved with the use of single domain antibody platforms, which is driving their demand. Developing countries such as India and China are poised for growth due to rising drug development activities. Global collaborations among leading research institutes are supporting research in drug discovery and molecular biology, thus driving market expansion.
Key Market Growth Drivers
- The market for single-domain antibody platforms is expanding due to several important factors. Innovative single-domain antibody platform solutions are being developed as a result of technological advancements.
- Sales of single domain antibody platforms in the pharmaceutical and biotechnology sectors are projected to rise significantly due to advancements in the drug development process, increasing medical research aimed at finding new and inventive drugs, and the growing need for sophisticated preclinical testing techniques.
- The market is witnessing partnerships and collaborations as well as acquisitions as inorganic growth strategies.
| Report Attributes | Details |
|---|---|
| Single Domain Antibody Platform Market Size (2024E) | US$ 32.9 Million |
| Forecasted Market Value (2034F) | US$ 86 Million |
| Global Market Growth Rate (2024 to 2034) | 10.1% CAGR |
| East Asia Market Share (2024E) | 12.6% |
| North America Market Share (2024E) | 40.5% |
| Camelids Segment Value (2024E) | US$ 30.2 Million |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Properties of Single Domain Antibodies are Driving Their Extensive Adoption?
“Role in Improving Bioavailability in Pharmaceutical Applications”
Single domain antibodies are known for their superior stability and resilience in extreme conditions. They offer a range of advantageous features. Among these is their outstanding penetrability, enabling them to traverse the blood-brain barrier with ease. They exhibit a unique capability to recognize epitopes inaccessible to conventional antibodies.
They contribute to improving bioavailability in pharmaceutical applications, which further enhances their utility. These antibodies are versatile, amenable to downstream engineering such as bispecific antibody creation and humanization, and can be efficiently expressed in both eukaryotic and prokaryotic systems. With such versatility and adaptability, single domain antibodies are emerging as invaluable tools for medical research, disease detection and treatment, and advancements in biotechnology.
What’s Stunting Demand for Single Domain Antibody Platforms?
“Stringent Regulatory Requirements and High Antibody Maintenance Costs”
The market faces constraints such as high antibody maintenance costs and a shortage of qualified professionals. Stringent regulations imposed by various regulatory bodies are projected to impede the adoption of single domain antibody platforms over the forecast period. Regulatory approval requires scrutiny of critical quality attributes (CQAs), antibodies, consumable cell lines, production equipment, and the final product, along with the entire process.
Obtaining antibodies from camelid species, a primary source, is a challenge due to the need for specialized facilities. To prevent immunological response heterogeneity, multiple animals and rigorous examination of specific immunization procedures, such as DNA immunization, are required. This is a significant obstacle to maintaining process effectiveness and creates challenges to market expansion.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
In terms of revenue, North America holds 40.5% of the global single domain antibody platform market share in 2024. The market in North America is projected to expand at a significant pace over the next 10 years. East Asia accounts for 12.6% share of the global market. The need for better healthcare treatment in East Asia and North America is projected to drive market expansion in these regions.
How is the Single Domain Antibody Platform Market Faring in the United States?
“Rising Cases of Cancer Boosting Demand for Antibodies”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 11 Million |
| Growth Rate (2024 to 2034) | 11.7% CAGR |
| Projected Value (2034F) | US$ 33 Million |
The United States holds a leading 80% share of the North American market in 2024 due to a rise in cancer cases and a commitment to creating better treatment alternatives for people. The country is witnessing technological advancements initiated by manufacturers to enhance the healthcare sector of the country.
Which Single Domain Antibody Platform Market Trends are Benefitting Companies in China?
“Heavy Investments in Healthcare Research and Rising Awareness of Advanced Treatment Options”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 1.9 Million |
| Growth Rate (2024 to 2034) | 11.4% CAGR |
| Projected Value (2034F) | US$ 5.7 Million |
China accounts for 46.1% market share in East Asia in 2024 as a result of robust research efforts in the healthcare sector. The single domain antibody platform market growth in China is also projected to be driven by rising healthcare spending and increasing awareness of cutting-edge treatments.
Category-wise Insights
The single domain antibody platform market is primarily categorized into platform types such as multi-specific, bispecific, mono-specific, and multivalent and by source into camelids and sharks. Camelids account for a market share of 90% in 2024. Antibodies from camelids are used in diagnostic laboratories (accounting for 19.3% market share), therapeutic development (44.8% market share), and research and development activities (36% market share).
Why Do Multi-Specific Single Domain Antibodies Account for Significant Market Share?
“Ability of Multi-specific Antibodies to Identify Multiple Epitopes on Same or Different Targets”
| Attribute | Multi-Specific |
|---|---|
| Segment Value (2024E) | US$ 10.8 Million |
| Growth Rate (2024 to 2034) | 11.4% CAGR |
| Projected Value (2034F) | US$ 31.7 Million |
Multi-specific antibodies have the unique ability to identify two or more epitopes on either the same or different targets. These engineered molecules address medical needs that were previously unmet by single-targeting approaches, such as monoclonal antibodies or cytokines alone, thanks to the added versatility afforded by protein design.
Due to the challenges involved in the development process of these molecules, it appears that a new workflow for multi-specific molecules is imperative. The creation of a manual for multi-specifics is driven by a deep exploration of the molecular mechanisms underlying the successful assembly of building blocks into non-native quaternary structures.
Which Factors are Pushing Use of Camelid Antibodies?
“Small Size of Camelid Antibodies Facilitating Enhanced Epitope Accessibility”
| Attribute | Camelids |
|---|---|
| Segment Value (2024E) | US$ 30.2 Million |
| Growth Rate (2024 to 2034) | 10.2% CAGR |
| Projected Value (2034F) | US$ 80.1 Million |
Camelid antibodies are estimated to hold 91.8% share of the single domain antibody platform market in 2024. Camelid antibodies are smaller in size because of which they can detect various epitopes with minimum steric hindrance, thus fueling the growth of this segment. Their small size enables them to access epitopes that larger antibodies may struggle to bind to.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the single domain antibody platform market are Hybrigenics Services, Oak BioSciences Inc., NeoClone Biotechnology International LL, GenScript, Rockland Immunochemicals Inc., ProSci Incorporated, BioCat GmbH, Creative Biolabs A, Sanyou Biopharmaceuticals Co. Ltd., Abiocenter, Antibody Design Labs, Synbio Technologies, Kaneka Eurogentec S.A., and ProteoGenix.
- At the 2023 Antibody Engineering & Therapeutics Conference, which was held in San Diego and organized by The Antibody Society, OmniAb, Inc. announced that it would be presenting new scientific data on its OmnidAb platform-the first and only transgenic chicken host system in the industry that produces single domain antibodies, or sdAbs. In a presentation titled “Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding,” Christine Vuong, Ph.D., Senior Scientist, gave an overview of OmnidAb and its capabilities to leaders in the industry and potential clients today.
Segmentation of Single Domain Antibody Platform Market Research
-
By Type :
- Multi-specific
- Bispecific
- Multivalent
- Mono-specific
-
By Animal Source :
- Camelids
- Camels
- Llamas
- Alpacas
- Sharks
- Camelids
-
By Application :
- Diagnostic Development
- Therapeutic Development
- Research and Development Activities
-
By End User :
- Diagnostic Laboratories
- Clinical Laboratories
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
-
By Region :
- North America
- Europe
- East Asia
- Latin America
- Middle East & Africa
- South Asia & Oceania
- FAQs -
How big is the single domain antibody platform market size in 2024?
The global single domain antibody platform market is estimated at US$ 32.9 million in 2024.
Which country has a significant market share?
The United States is estimated to account for a market valuation of US$ 11 million in 2024.
What is the estimated market size of Japan for 2024?
The market in Japan is forecasted to reach US$ 1.6 million by 2024.
What type of platform holds a key share of single domain antibodies?
Multi-specific single domain antibody platforms account for a market share of around 32% in 2024.
What is the market value derived from camelids in 2024?
Revenue from single domain antibodies derived from camelids is set to reach US$ 30.2 million in 2024.
What is the value of the pharmaceutical and biotechnology companies segment?
Sales from pharmaceutical and biotechnology companies are set reach US$ 12.1 million in 2024.
Single Domain Antibody Platform Market
*Mail attachment includes 219 figures & 80 tables